Stimulation of fracture mineralization by salt-inducible kinase inhibitors
Ontology highlight
ABSTRACT: Over 6.8 million fractures are reported annually in the US, accounting for 20% of all musculoskeletal injuries. Approximately 10% of fractures will experience delayed- or non-union. Parathyroid hormone (PTH) analogs and anabolic osteoporosis therapeutics can stimulate fracture repair in animal models and patients with chronic nonunion. Previous studies have demonstrated that small molecule salt inducible kinase (SIK) inhibitors mimic PTH action in vitro and in vivo. Therefore, we hypothesize that YKL-05-099, a small molecule SIK inhibitor, will accelerate fracture callus osteogenesis.
ORGANISM(S): Mus musculus
PROVIDER: GSE266115 | GEO | 2024/09/01
REPOSITORIES: GEO
ACCESS DATA